Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (171-180 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|December 9, 2015
Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease ModelBeatriz E Ferro, Shashikant Srivastava, Devyani Deshpande, et al.
Ebiomedicine|May 24, 2016
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in BabiesShashikant Srivastava, Jotam G Pasipanodya, Geetha Ramachandran, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsShashikant Srivastava, Devyani Deshpande, Gesham Magombedze, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2020
Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with TerizidoneMaxwell T Chirehwa, Richard Court, Mariana de Kock, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation studyKrina Mehta, Shruthi Ravimohan, Jotam G Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|July 26, 2021
Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis PatientsMaxwell T Chirehwa, Richard Court, Mariana de Kock, et al.
International Journal of Antimicrobial Agents|September 19, 2023
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimenSanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, et al.
Ebiomedicine|February 13, 2016
Poor Penetration of Antibiotics Into Pericardium in Pericardial TuberculosisJustin Shenje, F Ifeoma Adimora-Nweke, Ian L Ross, et al.
BMC Infectious Diseases|June 3, 2016
Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept studyIsaac Zentner, Hans P Schlecht, Lorna Khensouvann, et al.
The Journal of Infectious Diseases|January 1, 2019
Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Shashikant Srivastava, et al.
Pageof 21

Showing results (171-180 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|December 9, 2015
Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease ModelBeatriz E Ferro, Shashikant Srivastava, Devyani Deshpande, et al.
Ebiomedicine|May 24, 2016
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in BabiesShashikant Srivastava, Jotam G Pasipanodya, Geetha Ramachandran, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsShashikant Srivastava, Devyani Deshpande, Gesham Magombedze, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2020
Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with TerizidoneMaxwell T Chirehwa, Richard Court, Mariana de Kock, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation studyKrina Mehta, Shruthi Ravimohan, Jotam G Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|July 26, 2021
Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis PatientsMaxwell T Chirehwa, Richard Court, Mariana de Kock, et al.
International Journal of Antimicrobial Agents|September 19, 2023
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimenSanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, et al.
Ebiomedicine|February 13, 2016
Poor Penetration of Antibiotics Into Pericardium in Pericardial TuberculosisJustin Shenje, F Ifeoma Adimora-Nweke, Ian L Ross, et al.
BMC Infectious Diseases|June 3, 2016
Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept studyIsaac Zentner, Hans P Schlecht, Lorna Khensouvann, et al.
The Journal of Infectious Diseases|January 1, 2019
Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Shashikant Srivastava, et al.
Pageof 21